Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

OGI Investment will Fund Proteomic and Transcriptomic Analyses to Further Understand Stem Cells

Published: Thursday, November 15, 2012
Last Updated: Thursday, November 15, 2012
Bookmark and Share
The investment will be used to conduct studies required to apply for approval to initiate human clinical trials.

The Ontario Genomics Institute (OGI), through its Pre-Commercialization Business Development Fund (PBDF), has invested in Toronto-based Tissue Regeneration Therapeutics (TRT), a company that aims to use umbilical mesenchymal stem cells (MSCs) to treat a variety of serious medical conditions. 

MSCs are cells that can differentiate into musculoco-skeletal tissues such as bone, cartilage and muscle. Their ability to generate replacement tissues and affect cellular processes such as inflammation makes them an exciting potential therapy for a variety of conditions. Unlike other cells, MSCs can be used without the need for tissue matching and can be accumulated in large numbers. TRT has developed new methods to extract MSCs from umbilical cords, eliminating many of the challenges related to MSC harvesting from other tissue sources. 

“Stem cell research is a promising area of biomedical research and it could have significant impact for people suffering from many conditions,” said Mark Poznansky, President and CEO, OGI. “TRT is an excellent example of an Ontario company developing innovative therapies and translating research into potential clinical applications.”

TRT is aiming to launch clinical trials to test these cells within the next two years.  The PBDF funding from OGI will fund proteomic and transcriptomic analyses to further understand TRT’s stem cells. These studies will provide valuable information needed for regulatory approval to conduct human clinical trials and further differentiate their product from those of competitors.

“We believe that these stem cells represent a unique and potent means of treating multiple debilitating diseases,” said John Davies, CEO of TRT. “The OGI funding will enable us to demonstrate the utility of our cells for clinical applications using cutting edge technologies.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Proteins in Blood of Heart Disease Patients May Predict Adverse Events
Nine-protein test shown superior to conventional assessments of risk.
Self-Assembling Protein Shell for Drug Delivery
Made-to-order nano-cages open possibilities of shipping cargo into living cells or fashioning small chemical reactors.
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Nanoprobe Enables Measurement of Protein Dynamics in Living Cells
Mass. General and Harvard researchers use device to measure how anesthetic affects levels of Alzheimer's-associated proteins.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
A New Tool Brings Personalized Medicine Closer
Scientists from EPFL and ETHZ have developed a powerful tool for exploring and determining the inherent biological differences between individuals, which overcomes a major hurdle for personalized medicine.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
‘Missing Tooth’ Hydrogels Handle Hard-to-Deliver Drugs
Rice University’s custom hydrogel traps water-avoiding molecules for slow delivery.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!